WP
PCSA icon

WealthPLAN Partners’s Processa Pharmaceuticals PCSA Stock Holding History

WealthPLAN Partners’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2
Closed -$500 – 1360
2023
Q1 		$500 Buy
+2
New +$806 ﹤0.01% 1248

Other funds holding PCSA

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.62B AUM 36.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

WealthPLAN Partners's PCSA Position: Q2 2023 in Review

WealthPLAN Partners sold out of Processa Pharmaceuticals (PCSA) in Q2 2023, closing a stake of 2 shares — an estimated $500 sold.

WealthPLAN Partners first reported a position in PCSA in Q1 2023 and held it in 1 quarter. The position peaked at $500 in Q1 2023. 18 funds tracked by Wall St. Rank hold PCSA as of Q2 2023.

  • WealthPLAN Partners reported no remaining Processa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 2 Processa Pharmaceuticals shares in Q2 2023, an estimated $500.
  • WealthPLAN Partners first reported a position in Processa Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • WealthPLAN Partners's Processa Pharmaceuticals position peaked at $500 in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2023.

Based on WealthPLAN Partners's 13F filing for Q2 2023, filed 31 Jul 2023.